Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients

Neuromuscular Disorders

Volumn 20, Issue 4, 2010, Pages 251-254

  Helderman van den Enden, A T J M ^a   Straathof, C S M ^a   Aartsma Rus, A ^a   den Dunnen, J T ^a   Verbist, B M ^a   Bakker, E ^a   Verschuuren, J J G M ^a   Ginjaar, H B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Becker muscular dystrophy; Databases; Duchenne muscular dystrophy; Exon 51; Exon skipping therapy; Mild phenotype

Indexed keywords

CREATINE KINASE; DYSTROPHIN;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BECKER MUSCULAR DYSTROPHY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; EXON; FAMILY; GENE DELETION; HUMAN; LEG CRAMP; MALE; MOLECULAR WEIGHT; MUSCLE BIOPSY; MUSCLE CRAMP; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCLE WEAKNESS; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; WESTERN BLOTTING;

ADOLESCENT; AGED; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DYSTROPHIN; EXONS; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; OLIGORIBONUCLEOTIDES, ANTISENSE; OPEN READING FRAMES; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 77950955983     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.01.013     Document Type: Article

References (22)

1. Van Deutekom J.C., Janson A.A., Ginjaar H.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357:2677-2686.
2. Aartsma-Rus A., Fokkema I., Verschuuren J., et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009, 30:293-299.
3. White S.J., den Dunnen J.T. Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res 2006, 115:240-246.
4. Beenakker E.A., Maurits N.M., Fock J.M., et al. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Eur J Paediatr Neurol 2005, 9:387-393.
5. Morandi L., Mora M., Confalonieri V., et al. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype. J Neurol Sci 1995, 132:146-155.
6. Saengpattrachai M., Ray P.N., Hawkins C.E., et al. Grandpa and I have dystrophinopathy?: approach to asymptomatic hyperCKemia. Pediatr Neurol 2006, 35:145-149.
7. Torelli S., Brown S.C., Jimenez-Mallebrera C., et al. Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol Appl Neurobiol 2004, 30:540-545.
8. Lesca G., Testard H., Streichenberger N., et al. Family study allows more optimistic prognosis and genetic counselling in a child with a deletion of exons 50-51 of the dystrophin gene. Arch Pediatr 2007, 14:262-265.
9. Morandi L., Mora M., Tedeschi S., et al. DMD and BMD in the same family due to distinct mutations. Am J Med Genet 1995, 59:501-505.
10. Young H.K., Barton B.A., Waisbren S., et al. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol 2008, 23:155-162.
11. Chamberlain J.S., Gibbs R.A., Ranier J.E., et al. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res 1988, 16:11141-11156.
12. Beggs A.H., Koenig M., Boyce F.M., Kunkel L.M. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990, 86:45-48.
13. Schwartz M., Duno M. Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method. Genet Test 2004, 8:361-367.
14. Muntoni F., Di L.A., Porcu M., et al. Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy. Heart 1997, 78:608-612.
15. Bies R.D., Caskey C.T., Fenwick R. An intact cysteine-rich domain is required for dystrophin function. J Clin Invest 1992, 90:666-672.
16. Rafael J.A., Cox G.A., Corrado K., et al. Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 1996, 134:93-102.
17. Ferreiro V., Giliberto F., Muniz G.M., et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 2009, 39:239-243.
18. Miyazaki D., Yoshida K., Fukushima K., et al. Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene. J Hum Genet 2009, 54:127-130.
19. Nakamura A., Yoshida K., Fukushima K., et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 2008, 15:757-763.
20. Cotton R.G., Auerbach A.D., Axton M., et al. GENETICS: the human variome project. Science 2008, 322:861-862.
21. Kleinsteuber K., Rocco P., Herrera L., et al. Post exercise myalgias as presentation form of dystrophinopathy. Rev Med Chil 2000, 128:772-777.
22. Sironi M., Bardoni A., Felisari G., et al. Transcriptional activation of the non-muscle, full-length dystrophin isoforms in Duchenne muscular dystrophy skeletal muscle. J Neurol Sci 2001, 186:51-57.